Pre-operative chemotherapy for colorectal cancer liver metastases: An update of recent clinical trials

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 209-218

  Nasti, G ^a   Ottaiano, A ^a   Berretta, M ^b   Delrio, P ^c   Izzo, F ^c   Cassata, A ^a   Romano, C ^a   Facchini, G ^a   Scala, D ^c   Mastro, A ^c   Romano, G ^c   Perri, F ^a   Iaffaioli, R V ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Colorectal cancer; Liver metastases; Neoadjuvant; Resection

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PLACEBO;

ARTERY THROMBOSIS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; FATTY LIVER; FEASIBILITY STUDY; HEART INFARCTION; HUMAN; HYPERTENSION; INOPERABLE CANCER; INTESTINE PERFORATION; LIVER DISEASE; LIVER FIBROSIS; LIVER HYPERPLASIA; LIVER METASTASIS; LIVER NECROSIS; LIVER RESECTION; LIVER SINUSOID; LIVER TOXICITY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PORTAL VEIN THROMBOSIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; SHORT SURVEY; SIDE EFFECT; SURGICAL APPROACH; WOUND HEALING IMPAIRMENT; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 77953035157     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1297-x     Document Type: Short Survey

References (47)

1. Bonadonna G, Robustelli della Cuna G, Valagussa P (2009) Medicina Oncologica VII.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al (2004) Cancer statistics. CA Cancer J Clin 54:8-29
3. Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. World J Surg 19:59-71
4. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522
5. Adson MA (1987) Resection of liver metastases: when is it worthwhile? World J Surg 11:511-520
6. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938-946
7. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K et al (2003) Therapeutic results of hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46:22-31
8. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016
9. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J et al (1986) Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73:727-731
10. Poston G, Haller D, Kahan J, Cornelis M, Mahyaoui S (2004) Individualize the treatment of liver metastases from colorectal cancer using RAND appropriateness method: oncosurge decision modelresults of a consensus detecting from the international task force group. J Clin Oncol 22 (abstr 3595)
11. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al (1996) Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77:1254-1262
12. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189:291-299
13. Adam V, Delvart G, Pascal D, Castaing D, Azoulay S, Giachetti B et al (2004) Resection of non resectable liver metastases after chemotherapy: prognostic factors and long-term results. J Clin Oncol 22 (abstr 3550)
14. Mala T, Bohler G, Mathisen O, Bergan A, Søreide O (2002) Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg 26:1348-1353
15. Quispe IR, Ramos FJ, Bilbao I, Macarulla T, Cedres S, Charco R et al (2009) Long-term overall survival (os) and prognostic factors of patients (pts) with surgery of liver metastases from colorectal cancer origin (lm/crc): Retrospective analysis of a Spanish single institution. J Clin Oncol 27 (abstr 15052)
16. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22:229-237
17. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK et al (2004) A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
18. Falcone A, Ricci S, Brunett I, Pfanner E, Allegrini G, Barbara C et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as Wrstline treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676
19. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal (liver) metastases. Ann Surg Oncol 8:347-353
20. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669
21. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829-1835
22. Alberts SR, Donohue JH, Mahoney MR, Horvath WL, Sternfeld WC, Dakhil SR et al (2003) Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: a north central cancer treatment group (NCCTG) phase II study. J Clin Oncol 22 (abstr 1053)
23. Quenet F, Nordlinger B, Rivoire M, Delpero JR, Portier G, Mery- Mignard D et al (2004) Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) afer chemotherapy (CT) with CPT-11/L-OHP/LV5FU (FolWrinox): a prospective phase II trial. J Clin Oncol 22 (abstr 3613)
24. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N et al (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933-939
25. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939-3945
26. Gruenberger T, Schuell B, Kornek G, Scheithauer W (2004) Neoadjuvant chemotherapy for resectable colorectal cancer liver metastasis: impact on magnitude of liver resection and survival. J Clin Oncol 22 (abstr 3598)
27. Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T et al (2005) Intensive systemic chemotherapy combined with surgery formetastatic colorectal cancer: results of a phase II study. J Clin Oncol 23:502-509
28. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072
29. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845-853
30. Adam R, Sebagh M, Plasse M, Karam V, Giachetti S, Azoulay D et al (2005) Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM). J Clin Oncol 23 (abstr 3529)
31. Wicherts DA, De Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B et al (2009) Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases. J Clin Oncol 27 (abstr 4097)
32. Nordlinger B, Benoist S (2006) Benefits risks of neoadjuvant therapy for liver metastases. J Clin Oncol 24:4954-4955
33. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
34. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of Bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712
35. Giantonio BJ, Catalano PJ, Meropol NJ, Mitchell EP, Schwartz MA, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544
36. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180
37. Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastases in the era of bevacizumab. J Clin Oncol 23:4853-4855
38. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F et al (2008) Bevacizumab, Capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metatsatic colorectal cancer. J Clin Oncol 26:1830-1835
39. Michael M, Van Cutsem E, Kretzschmar A, Berry S, Rivera F, Dibartolomeo M et al (2006) Feasibility of metastasectomy in patients treated with bevacizumab in Wrst-line mCRC: preliminary results from the First Beat-study. J Clin Oncol 24 (abstr 3523)
40. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as Wrst-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
41. Bouganim N, Kavan P, Eid M, Metrakos P, Chaudhury P, Batist G (2009) Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. J Clin Oncol 27 (abstr e15027)
42. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer livermetastases. Eur J Surg Oncol 35:515-520
43. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593-4602
44. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT et al (2010) Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38-47
45. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
46. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the Wrst-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
47. Garufi C, Torsello A, Tumolo S, Mottolese M, Campanella C, Zeuli M et al (2009) POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 27 (abstr e15020)